These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
204 related articles for article (PubMed ID: 6006069)
41. Rifampin 1200 mg once monthly together with daily Lamprene and dapsone in treatment of refactory patients with lepromatous leprosy. Paul S; Rose ET Int J Lepr Other Mycobact Dis; 1981 Sep; 49(3):342-3. PubMed ID: 7198625 [No Abstract] [Full Text] [Related]
42. Prevalence survey of secondary dapsone resistance in leprosy in Kancheepuram and Tiruvannamalai control units of Tamil Nadu. Neelan PN; Noordeen SK; Balakrishnan S; Pandian PR Lepr India; 1983 Apr; 55(2):222-30. PubMed ID: 6355650 [TBL] [Abstract][Full Text] [Related]
43. [Current concepts in the treatment of Hansen's disease]. Languillon J Acta Leprol; 1980; (81):49-57. PubMed ID: 6785983 [No Abstract] [Full Text] [Related]
44. Secondary sulphone resistance in leprosy (Report of a case). Lal S; Jaganath C; Garg BR; Paneerselvam R Lepr India; 1980 Apr; 52(2):299-301. PubMed ID: 7005542 [TBL] [Abstract][Full Text] [Related]
45. A retrospective study of the effect of modified multi-drug therapy in Nepali leprosy patients following the development of adverse effects due to dapsone. Sapkota BR; Shrestha K; Pandey B; Walker SL Lepr Rev; 2008 Dec; 79(4):425-8. PubMed ID: 19274989 [TBL] [Abstract][Full Text] [Related]
46. The promin treatment of leprosy. A progress report. Faget GH; Pogge RC; Johansen FA; Dinan JF; Prejean BM; Eccles CG Int J Lepr Other Mycobact Dis; 1966; 34(3):298-310. PubMed ID: 5950351 [No Abstract] [Full Text] [Related]
47. Dapsone levels after oral therapy and weekly oily injections in Ethiopian leprosy patients. Modderman ES; Merkus FW; Zuidema J; Hilbers HW; Warndorff T Int J Lepr Other Mycobact Dis; 1983 Jun; 51(2):191-6. PubMed ID: 6684645 [No Abstract] [Full Text] [Related]
48. The prevalence of folP1 mutations associated with clinical resistance to dapsone, in Mycobacterium leprae isolates from South Korea. Lee SB; Kim SK; Kang TJ; Chae GT; Chun JH; Shin HK; Kim JP; Ko YH; Kim NH Ann Trop Med Parasitol; 2001 Jun; 95(4):429-32. PubMed ID: 11454253 [No Abstract] [Full Text] [Related]
49. Monitoring the regularity of self administration of dapsone by leprosy patients. Kumar A; Balakrishnan S Lepr India; 1982 Oct; 54(4):664-70. PubMed ID: 7183832 [TBL] [Abstract][Full Text] [Related]
50. Streptomycin combined with sulfones in the treatment of relapsed lepromatous leprosy. McDougall AC; Hastings RC Int J Lepr Other Mycobact Dis; 1968; 36(4):456-7. PubMed ID: 5753815 [No Abstract] [Full Text] [Related]
51. The pharmacology of sulphetrone and its implications in sulphone resistance. Gelber RH; Gooi HC; Waters MF; Rees RJ Lepr Rev; 1974 Dec; 45(4):308-12. PubMed ID: 4444392 [No Abstract] [Full Text] [Related]
52. Co-incident (simultaneous) dapsone sensitive and dapsone resistant leprosy. McDougall AC; Ross WF Int J Lepr Other Mycobact Dis; 1982 Jun; 50(2):214-5. PubMed ID: 6749709 [No Abstract] [Full Text] [Related]
53. Oral zinc as an adjunct to dapsone in lepromatous leprosy. Mathur NK; Bumb RA; Mangal HN; Sharma ML Int J Lepr Other Mycobact Dis; 1984 Sep; 52(3):331-8. PubMed ID: 6541200 [TBL] [Abstract][Full Text] [Related]
54. Drug resistance in leprosy: lessons from past and future perspective. Gupta UD; Katoch VM Indian J Lepr; 1999; 71(4):451-63. PubMed ID: 10804973 [TBL] [Abstract][Full Text] [Related]
55. [Treatment of leprosy by sulfones and delayed-action sulfonamides: comparison of therapeutic results in 100 cases]. Privat Y; Faye I; Bellossi A Mars Med; 1968; 105(3):276-80. PubMed ID: 5754252 [No Abstract] [Full Text] [Related]